Insulintropic actions of intravenous glucagon-like peptide-1 (GLP-1) (7-36 amide) in the fasting state in healthy subjects

Key Points

• Increased insulin secretion contributes to better glucose control with GLP-1 administration, promoting its therapeutic potential.
• A significant hypoglycaemic response was noted, indicating glucagon-like peptide 1's role in managing blood sugar levels.
• Assessment involved fasting healthy subjects receiving intravenous GLP-1 (7-36 amide) to evaluate its role in insulin response.
• Highlights the potential therapeutic applications of incretin hormones for metabolic health, warranting further research.